Neurobehavioral and biochemical responses to artemisinin-based drug and aflatoxin B1 co-exposure in rats

被引:0
作者
Isaac A. Adedara
Solomon E. Owumi
机构
[1] University of Ibadan,Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine
[2] University of Ibadan,Cancer Research and Molecular Biology Laboratory, Department of Biochemistry, College of Medicine
来源
Mycotoxin Research | 2023年 / 39卷
关键词
Aflatoxin B; Artemisinin; Co-exposure; Apoptosis; Neurotoxicity;
D O I
暂无
中图分类号
学科分类号
摘要
Populations in malaria endemic areas are frequently exposed to mycotoxin-contaminated diets. The possible toxicological outcome of co-exposure to dietary aflatoxin B1 (AFB1) and artemisinin-based combination therapy warrants investigation to ascertain amplification or attenuation of cellular injury. Here, we investigated the neurobehavioral and biochemical responses associated with co-exposure to anti-malarial drug coartem, an artemether-lumefantrine combination (5 mg/kg body weight, twice a day and 3 days per week) and AFB1 (35 and 70 µg/kg body weight) in rats. Motor deficits, locomotor incompetence, and anxiogenic-like behavior induced by low AFB1 dose were significantly (p < 0.05) assuaged by coartem but failed to rescue these behavioral abnormalities in high AFB1-dosed group. Coartem administration did not alter exploratory deficits typified by reduced track plot densities and greater heat map intensity in high AFB1-dosed animals. Furthermore, the reduction in cerebral and cerebellar acetylcholinesterase activity, anti-oxidant enzyme activities, and glutathione and thiol levels were markedly assuaged by coartem administration in low AFB1 group but not in high AFB1-dosed animals. The significant attenuation of cerebral and cerebellar oxidative stress indices namely reactive oxygen and nitrogen species, xanthine oxidase activity, and lipid peroxidation by coartem administration was evident in low AFB1 group but not high AFB1 dose. Although coartem administration abated nitric oxide level, activities of myeloperoxidase, caspase-9, and caspase-3 in animals exposed to both doses of AFB1, these indices were significantly higher than the control. Coartem administration ameliorated histopathological and mophometrical changes due to low AFB1 exposure but not in high AFB1 exposure. In conclusion, contrary to AFB1 alone, behavioral and biochemical responses were not altered in animals singly exposed to coartem. Co-exposure to coartem and AFB1 elicited no additional risk but partially lessened neurotoxicity associated with AFB1 exposure.
引用
收藏
页码:67 / 80
页数:13
相关论文
共 268 条
  • [21] Adedara IA(2002)Fimbria-fornix lesions disrupt the dead reckoning (homing) component of exploratory behavior in mice Learn Mem 9 387-1205
  • [22] Nanjappa MK(2003)Heparin mobilizes xanthine oxidase and induces lung inflammation in acute pancreatitis Crit Care Med 31 525-139
  • [23] Farombi EO(1982)Analysis of nitrate, nitrite and [15N]nitrate in biological fluids Anal Biochem 126 131-169
  • [24] Akingbemi BT(1974)Glutathione S-transferase. The first enzymatic step in mercapturic acid formation J Biol Chem 249 7130-12
  • [25] Allen SJ(2022)Drug-drug interactions of artemisinin-based combination therapies in malaria treatment: a narrative review of the literature J Clin Pharmacol 62 1197-766
  • [26] Wild CP(2014)Artemisinins: pharmacological actions beyond anti-malarial Pharmacol Ther 142 126-213
  • [27] Wheeler JG(1974)Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3,4 bromobenzene oxide as the hepatotoxic metabolite Pharmacology 11 151-436
  • [28] Riley EM(1997)Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro Am J Trop Med Hyg 56 7-9
  • [29] Montesano R(2020)The noncanonical pathway for in vivo nitric oxide generation: the nitrate-nitrite-nitric oxide pathway Pharmacol Rev 72 692-237
  • [30] Bennett S(2016)Heavy metals (Pb, Cd, As and MeHg) as risk factors for cognitive dysfunction: a general review of metal mixture mechanism in brain Environ Toxicol Pharmacol 48 203-3181